The University of Arizona College of Pharmacy had an exceptional presence at the recent American Society of Oncology (ASCO) Annual Meeting in Chicago. The event is described as the world's largest scientific cancer meeting, with 43,000 people in attendance.
The Hematology/Oncology Research Group led by Ali McBride, PharmD, MS, BCPS, BCOP, Assistant Professor of Pharmacy Practice and Science, and Ivo Abraham, PhD, RN, Professor of Pharmacy Practice had eleven abstracts published in the Journal of Clinical Oncology. Two posters were presented by PhD candidates Mok Oh and Nimer Alkhatib (pictured above). Both posters attracted tremendous interest with heavy traffic.
Publications
- Hinchman A, Abraham I, Almutairi A, Sundararajan S, Lattimore L, Babiker H, McBride A. Clinical experience with talimogene laherparepvec (Imlygic®) in a melanoma population at a university-based cancer center. Journal of Clinical Oncology 2018;36(Suppl):e21547.
- Oh M, Aljadeed R, Al Khushaym N, Althagafi A, Fallatah S, Babiker H, McBride A, Abraham I. The association of BRCA1 and BRCA2 mutations on prostate cancer risk, frequency, and mortality: systematic review and meta-analysis. Journal of Clinical Oncology 2018;36(Suppl):5060.
- Oh M, Almutairi A, Alkhatib N, Babiker H, McBride A, Abraham I. Progression-free and overall survival in treatment of BRAF mutation-positive metastatic melanoma: Bayesian network meta-analysis. Journal of Clinical Oncology 2018;36(Suppl):e21532.
- Fletcher S, Alkhatib N, Katragadda C, Martin J, Babiker H, Algotar A, McBride A, MacDonald K, Abraham I. Risk of biochemical recurrence in prostate cancer patients with perineural invasion: systematic review and meta-analysis. Journal of Clinical Oncology 2018;36(Suppl):e216761.
- Garcia A, Frahm C, Jeter J, Abraham I, Chambers S, Cragun J, McBride A. Incidence of hypersensitivity reactions to carboplatin or paclitaxel in patients with ovarian, fallopian tube, or primary peritoneal cancer with or without BRCA1 or BRCA2 mutations. Journal of Clinical Oncology 2018;36(Suppl):e18758.
- Alhifany A, McBride A, Almutairi A, Babiker H, MacDonald K, Abraham I. Efficacy of thalidomide, neurokinin-1 receptor antagonist, and olanzapine in combination with palonosetron plus dexamethasone in preventing chemotherapy-induced nausea and vomiting induced by highly emetogenic chemotherapy: Bayesian network meta-analysis. Journal of Clinical Oncology 2018;36(Suppl):e14514.
- Almutairi A, Alkhatib N, Martin J, Babiker H, McBride A, Abraham I. Comparative efficacy and safety of immunotherapies targeting PD-1/PD-L1 pathway for previously treated advanced non-small cell lung cancer: Bayesian network meta-analysis. Journal of Clinical Oncology 2018;36(Suppl):e21012.
- AlRawashdh N, McBride A, Lee C, Diri R, Bagalagel A, Bakhsh H, Babiker H, MacDonald K, Abraham I. Outcomes of pegfilgrastim administration on the same day vs the day after chemotherapy in the prophylaxis of chemotherapy-induced (febrile) neutropenia: systematic review and meta-analysis. Journal of Clinical Oncology 2018;36(Suppl):e14510.
- Tompkinson M, Fine K, Gruber D, Abraham I, Babiker H, McBride A. A survey of perceptions of healthcare workers on the cost and safety of oral oncolytic agents in practice. Journal of Clinical Oncology 2018;36(Suppl):e18926.
- Almutairi A, Alkhatib N, Oh M, Babiker H, McBride A, Abraham I. Economic evaluation of the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab in patients with advanced unresectable melanoma. Journal of Clinical Oncology 2018;36(Suppl):e21545.
- Alkhatib N, McBride A, Persky D, Anwer F, Andritsos L, Kumar A, Yun S, Babiker H, Abraham I. Economic evaluation for the US of venetoclax versus ibrutinib versus allogeneic hematopoietic stem-cell transplantation for patients with relapsed or refractory chronic lymphocytic leukemia with 17p deletion. Journal of Clinical Oncology 2018;36(Suppl):7527.